Human Immunodeficiency Virus and Hepatitis B Virus Dual Infection in Nepal
|Barnawal SP1*, Niraula SR2, Bista N1, Agrahari AK1, Jha N2 and Pokharel PK2|
|1B P Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal|
|2School of Public Health and Community Medicine, BPKIHS, Nepal|
|Corresponding Author :||Satish Prasad Barnawal
B P Koirala Institute of Health Sciences
Dharan, Sunsari, Nepal
E-mail: [email protected]
|Received March 25, 2014; Accepted May 02, 2014; Published May 10, 2014|
|Citation: Barnawal SP, Niraula SR, Bista N, Agrahari AK, Jha N, et al. (2014) Human Immunodeficiency Virus and Hepatitis B Virus Dual Infection in Nepal. J Infect Dis Ther 2:142. doi: 10.4172/2332-0877.1000142|
|Copyright: © 2014 Barnawal SP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infections are emerging public health problems, particularly in developing counties like Nepal. The study aims at finding prevalence and pattern of CD4 cell count among HBV co-infected HIV positive individuals in Nepal.
Methods: This is a descriptive cross-sectional study carried out in three Volunteer Counseling and Testing (VCT) clinics, one from Dharan and two from Kathmandu Nepal.
Results: 5.75% of HIV infected individuals had HBV dual infection. 33.4% of patients who harbored dual HIV and HBV infection had multiple sex partners. No significant association was observed between HBV co-infection and Injecting Drug Users (IDU). The mean CD4 cell count was found to be significantly more among HBV uninfected cases compared to HBV infected ones at six months’ duration (P=0.006) and one years’ duration (P=0.027) after taking anti-retroviral therapy (ART).
Conclusion: HBV co-infection was more among those having multiple sex partners. ART helped increase CD4 cell count among HBV co-infected and uninfected HIV positive patients, but the results were better among HIV mono-infected individuals.